Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We read with interest the article by Bruix et al1 in which Sorafenib was regarded as the standard treatment for hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT). However, Sorafenib can only confer 2–3 months of overall survival (OS) benefit2 ,3 and is inapplicable to many patients due to extensive side effects and high price. Zhong et al4 proposed that liver resection might provide survival benefit to patients with HCC-PVTT with adequate liver function. However, this proposal was based on literature survey, lacked definite patient inclusion criteria and failed to provide information on patients’ baseline characteristics. Therefore, explorations of alternative therapeutics for patients with HCC-PVTT are still needed.
Although not recommended by mainstream guidelines5 ,6 for patients with HCC-PVTT, transarterial chemoembolisation (TACE) has long been practiced in the clinic in selected patients with HCC-PVTT.7 ,8 Gamma knife surgery (GKS) has shown favourable effects in treating brain …
Xiao-Jie Lu, Jing Dong and Li-Juan Ji are co-first authors
Contributors JZ and L-XX performed part of the transarterial chemoembolisation and gamma knife surgery procedures. C-QL, JZ and X-JL designed the study. JZ and JD collected the data. J-HL, H-MC and X-JL conducted patient follow-ups. X-JL and L-JJ analysed the data and wrote the manuscript. All authors have read and approved the manuscript.
Funding Funded by ‘The 3-Year Promoting Program of Traditional Chinese Medicine by Shanghai Municipal Commission of Health and Family Planning (ZYSNXD-CC-ZDYJ023, ZY3-LCPT-2-1004)’.
Competing interests None declared.
Ethics approval Institutional Ethics Committee of Changhai Hospital.
Provenance and peer review Not commissioned; internally peer-reviewed.